Clinical trial for recurrent or progressive non-small-cell lung cancer
June 26th, 2009
ImClone Systems Incorporated is conducting a clinical trial for patients whose non-small cell lung cancer has recurred or continued to advance despite previous treatment. The goal of the trial is to compare the progression-free survival of patients treated with ERBITUX® (cetuximab) and Alimta® (pemetrexed) to progression-free survival of patients treated with three other combination chemotherapy regimens including TAXOTERE® (docetaxel).